York biotech Aptamer Group is laying the groundwork for growth after reaching an agreement with York Science Park (YPS) to expand their space.
This follows the company’s recent success in securing $2.2 million in Series A funding.
Aptamer Group is now able to drive forward is pre-clinical discovery programmes involving the development of aptamer drug conjugates (ApDCs) which are set to become a revolutionary approach to targeted drug delivery.
CEO Arron Tolley said: “We secured our funding on a solid business plan, strong sales pipeline and excellent data – which demonstrated aptamer technology as a viable drug delivery system.
“We were recognised, by investors with expertise in the development of biologic drugs, as a fast-growing UK biotechnology business.
“We planned our next steps jointly with YSP, taking into consideration our strategic plan for growth. Further embedding ourselves at YSP is the most logical strategy for us.
“It allows us to take advantage of the existing infrastructure and further expand our existing team of 18 people along with providing us with the facilities to focus on both R&D and our commercial works.”
This most recent expansion adds another two labs and two offices to its existing space of four offices and five labs, including a specialist robotics and preclinical discovery laboratories.
This expansion will take their total space to more than 3000 square feet, allowing the company’s team to set up a new, dedicated R&D laboratory and expand its existing commercial lab space to keep up with increased demands alongside expanding their office facilities to accommodate its growing team.
Claire Bennett, General Manager of York Science Park, said: “We were delighted to work with Aptamer Group to help them set their plans in place for the next two years. They are a really dynamic company, working in an incredibly innovative area of bio technology that is constantly evolving.
“We were very happy to help them secure space that allows them to grow their team and help them develop their strategy. We look forward to continuing to help support them in the future.”